Boston Trial to Test New HIV/AIDS Vaccine

Discussion Policy

Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.

Friday, April 11, 2008; 12:00 AM

FRIDAY, April 11 (HealthDay News) -- A new HIV/AIDS vaccine designed to overcome the problem of preexisting immunity to common vaccine vectors is being tested in an early clinical trial at Brigham and Women's Hospital in Boston.

Preexisting immunity is believed to be a major problem in developing nations.

There will be 48 healthy volunteers taking part in the trial of the vaccine, which consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.

Each volunteer will receive either two or three immunizations, and then be monitored to assess the safety of the vaccine and its ability to trigger an immune response.

The rAd26 vaccine was developed by the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program, sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The program brings together academic and industry researchers to accelerate development of promising HIV/AIDS vaccine candidates.

The vaccine, the first HIV-1 vaccine candidate to emerge from the IPCAVD program, is made by Dutch biotechnology company Crucell Holland B.V.

The approach used in developing the rAd26 vaccine enables researchers to circumvent preexisting immunity to serotype 5, the virus responsible for the common cold. This virus has recently shown limitations as an HIV-1 vaccine vector.

"The rAd26 vector does not regularly occur in the human population, and human antibodies to this vector are rare. The rAd26 vector therefore is efficacious in eliciting good T and B (immune) cell responses," Jaap Goudsmit, chief scientific officer at Crucell, said in a prepared statement.

About 33.2 million people worldwide are living with HIV/AIDS, and there were 2.7 million new infections reported in 2007.

More information

Currently, there is no vaccine to protect against HIV/AIDS. The American Academy of Family Physicians offers tips for preventing HIV infection.

SOURCE: Brigham and Women's Hospital, news release, April 3, 2008